Subscribe to Press release email alerts
Sign up for BMY email alerts and receive timely updates on press releases.
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Sign up for BMY email alerts and receive timely updates on press releases.
Source route
Continue on bms.com
Leave the platform to read the original full article on the publisher site.
Source: Mirati Therapeutics (BMS)
Scope: Industry
Related coverage
More related coverage
Karyopharm Announces $30 Million Private Placement with RA Capital
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering no...
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Di...
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company commi...